Vertex Pharmaceuticals, Inc. is a global biotechnology company in the business of discovering, developing, manufacturing and introducing small molecule medicines for patients with serious diseases. The company is based in Boston, Massachusetts and currently employs 3,900 full-time employees. The company is focused on developing drugs that treat the underlying causes of cystic fibrosis (CF) and has several ongoing clinical and research programs to advance and expand CF treatments. The company's introduced medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). Four of their drugs are used to treat people with CF in North America, Europe and Australia. The company has a pipeline of therapies under investigation in other serious diseases where it uses an understanding of the human biology that causes them, including cyclic cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and dystrophy. muscles. Other company pipeline products include CTX001, VX-147, VX-121, VX-561, VX-548, and VX-880.
Vertex Pharmaceuticals Inc Analytics and Performance
VRTX: A Company in the LIFE SCIENCES Sector and PHARMACEUTICAL PREPARATIONS Industry
Discover Vertex Pharmaceuticals Inc (VRTX), a prominent player in the LIFE SCIENCES sector, specifically within the PHARMACEUTICAL PREPARATIONS industry. As a Common Stock, VRTX has a strong presence not only in the United States but also in various countries around the world, including its home base USA.
VRTX Financial Performance: Key Ratios and Market Indicators
As of the latest quarter ending 2023-03-31, VRTX boasts an EBITDA of 4618400000 and a trailing price-to-earnings ratio (PE ratio) of 26.53. The forward PE ratio stands at 19.72, which indicates stocks potential in earnings. VRTX's price-to-sales ratio (TTM) is 9.1, and the price-to-book ratio is 6.15. The company's enterprise value-to-revenue and enterprise value-to-EBITDA ratios are 8.18 and 16.84, respectively.
VRTX Stock Stability: Analyzing Marketing Volatility and Trends
VRTX stock performance showcases a beta of 0.49, highlighting moderate volatility. The 52-week high and low prices are 354.46 and 243.17, respectively, with a 50-day moving average of 329.16 and a 200-day moving average of 306.32. With 257552000 shares outstanding, VRTX demonstrates strong performance in the market.
VRTX Dividends: Current Yields and Shareholder Value
In terms of dividends, Vertex Pharmaceuticals Inc has a dividend per share of 0 and a dividend yield of 0. The company's most recent dividend date was None, and the ex-dividend date was None. VRTX's financials reveal a book value of 56.05 and earnings per share (EPS) of 12.44, with a diluted EPS (TTM) of 12.44.
VRTX Revenue and Profitability: Unveiling the Company's Financial Strength
VRTX revenue per share (TTM) is 35.87, and its total revenue (TTM) amounts to 9208001000. The company's gross profit (TTM) is 5323100000. VRTX's profit margin stands at 0.354, while the operating margin (TTM) is 0.485. The return on assets (TTM) and return on equity (TTM) are 0.168 and 0.257, respectively.
VRTX Growth Prospects: Earnings Growth and Analyst Expectations
VRTX has experienced quarterly earnings growth (YOY) of -0.091, but its quarterly revenue growth (YOY) remains stagnant at 0.132. Analysts have set a target price of 345.84 for Vertex Pharmaceuticals Inc stock.
Interested in Vertex Pharmaceuticals Inc? You may be interested in:
Vertex Pharmaceuticals Inc stock
